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Abstract: There is no consensus on recommendations for the treatment of relapsed and refractory 
indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has 
recently been approved for treatment of these patients. Bendamustine is a uniquely structured 
alkylating agent that lacks cross-resistance with other alkylators. This agent has a high degree 
of activity against a variety of tumor cell lines. Clinically, bendamustine has demonstrated 
activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle 
cell lymphoma. Moreover, studies have validated its activity in patients with indolent NHL 
who are resistant to purine analogs and rituximab. The cytotoxic activity of bendamustine has 
been shown to be synergistic with rituximab in hematological malignancies. The incidence of 
alopecia is significantly less than with other alkylating agents. Myelosuppression is the major 
toxicity associated with bendamustine.
Keywords: bendamustine, Treanda, indolent non-Hodgkin lymphoma, alkylating agent, chronic 
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Introduction to management issues in the 
treatment of indolent non-Hodgkin lymphoma
The clinical behavior of non-Hodgkin lymphomas (NHL) is widely variable. For 
example, Burkitt lymphoma may be rapidly fatal in the absence of urgent therapy, 
whereas patients with follicular lymphoma (FL) may live for many years without 
any treatment. NHL accounts for approximately 5% of newly diagnosed cancers in 
men and 4% of newly diagnosed cancers in women.1 In 2009 it is estimated that there 
will be 65,980 new case of NHL diagnosed in the US, and that 19,500 people will 
die with this diagnosis. Indolent (low-grade) lymphomas comprise approximately 
40% of NHLs in the US. Follicular lymphoma is the most common type of indolent 
lymphoma accounting for approximately 20% to 25% of all lymphomas in the US. 
Although patients with indolent NHL usually have advanced-stage disease at the time 
of diagnosis, they are often asymptomatic. Long-term progression-free survival (PFS) 
can be observed following treatment for indolent NHL, but these patients are usually 
considered incurable with standard therapy.
Management of patients with indolent NHL has historically relied on a watch-and-
wait approach until evidence of symptomatic disease is present. It is still unknown 
whether overall survival (OS) is modified when treatment is initiated early for 
patients with nonbulky asymptomatic disease. Early studies prior to the introduc-
tion of rituximab failed to establish a survival benefit when treatment with chemo-
therapy was compared to a watch-and-wait approach.2–4 The survival of patients with Cancer Management and Research 2009:1 156
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follicular lymphoma has improved over the last 30 years.5 
This improvement is undoubtedly related in part to the use of 
rituximab combined with chemotherapy in primary treatment 
regimens.6–9 The use of rituximab with upfront chemotherapy 
is now considered standard. Although a watch-and-wait 
approach may still be indicated for selected patients, studies 
have shown that the majority (81%) of FL patients received 
therapy in the US.10
Therapy is indicated for patients with symptomatic 
or bulky disease. Several management options have been 
recommended including single agent chemotherapy or 
immunotherapy with rituximab, combination therapy, and 
high-dose chemotherapy followed by hematopoietic stem cell 
transplantation. The optimal chemotherapy regimen has not 
been defined. Alkylating agents (chlorambucil, cyclophos-
phamide) or purine analog (fludarabine)-based regimens are 
used most commonly.
Although the initial therapy for indolent NHL is 
associated with high response rates, the majority of 
patients will eventually relapse, with successive reduc-
tions in the length of response to each salvage regimen. 
Treatment of patients with relapsed or refractory indo-
lent NHL must be individualized. One evolving exciting 
area is the introduction of the radioimmunoconjugates 
(131I-tositumomab, 90Y-ibritumomab-tiuxetan), which have 
demonstrated significant activity for patients with pre-treated 
and previously untreated indolent NHL.11–15 Autologous and 
allogeneic hematopoietic stem cell transplantation may be 
considered for some patients with relapsed and refractory 
indolent lymphomas.16,17
New chemotherapy options are warranted for patients 
with indolent lymphomas. Bendamustine is an alkylating 
agent, which has been recently approved for use in the US. 
It has been associated with excellent response rates when 
used as monotherapy or in combination with monoclonal 
antibodies in patients with refractory NHL.
Review of bendamustine 
pharmacology
Bendamustine was initially manufactured in the former 
East German Democratic Republic in the early 1960s by 
Ozegowski et al in an attempt to create an antineoplastic 
agent exhibiting dual antitumor activity with a favorable 
toxicity profile.18 Until 1990, the use of bendamustine was 
primarily limited to East Germany. Following the German 
reunification, the use of bendamustine for a wide variety of 
hematologic malignancies and solid tumors has been inves-
tigated throughout the world.
Bendamustine structure
Bendamustine hydrochloride (Treanda®; Cephalon, Inc.) is 
a bifunctional alkylating agent with antimetabolite effects. 
Bendamustine has been recognized as a novel agent with 
exceptional function in different tumor cell lines.19–22 The 
distinctive activity of bendamustine is related to its unique 
structure (Figure 1). It consists of a nitrogen mustard 
(mechlorethamine) group, a characteristic element of alkyl-
ators such as chlorambucil and cyclophosphamide, simul-
taneously with a benzimidazole ring that substitutes for the 
benzene ring seen in chlorambucil. The benzimidazole ring 
is seen in purine-analogs, and may be responsible for the 
potential antimetabolic activity, although this has not been 
confirmed in vivo. In addition, the structure contains a butyric 
acid chain that makes bendamustine water-soluble.23,24 
Chemically, bendamustine is identified as 1H-benzimidazole-
2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-, 
monohydrochloride.
Mode of action
Although the bendamustine molecule has characteristics in 
common with alkylators and purine-analogs, the antineoplas-
tic activity is primarily related to the former. Bendamustine 
induces DNA damage through intra- and inter-strand cross-
linking of DNA base pairs, which subsequently leads to cell 
apoptosis. In addition, it causes stimulation of DNA damage 
stress response and apoptosis, down-regulation of mitotic 
checkpoints, and induction of mitotic catastrophe, which 
interrupts cell division.23,25 In contrast to other alkylating 
agents, the impact of bendamustine on DNA damage was 
verified to be more extensive, long-lasting and more resistant 
to repair, which might be attributed to the potency and lack 
of complete cross-resistance that distinguishes bendamustine 
from other alkylators.26,27
Bendamustine pharmacokinetics
Following the intravenous infusion of bendamustine, the 
mean peak plasma concentration (Cmax) occurs at the end 
of the infusion, and Cmax and the area under the plasma 
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concentration curve (AUC) shows independent relationship 
to the administered dose.28,29 At steady state, bendamustine 
has a volume of distribution (Vd) of 20 to 25 L.28–32
Bendamustine metabolism predominantly occurs through 
hydrolysis, and phase I metabolite formation seems to be 
mediated via hepatic cytochrome P450 1A2.33 Hydrolysis 
generates active and inactive metabolites. Nevertheless, 
active metabolites such as gamma-hydroxy-bendamustine 
(M3) and N-desmethyl-bendamustine (M4) occur in negli-
gible concentrations compared to the parent component, and 
this verified that the cytotoxic activity of bendamustine is 
mainly generated by the original compound. Nonmetabolized 
particles have been found to constitute 45% of the excreted 
portion of the drug in urine.33
Following a 60-minute intravenous administration in 
patients with NHL, serum bendamustine declined in a rapid 
biphasic manner (t½α = 17 minutes, t½β = 42 minutes) and 
a slow terminal phase (t½c = 110 hours), but the terminal 
phase composed less than 1% of the total AUC, and therefore, 
the half-life of the β-phase represents bendamustine mean 
half-life, which is approximately 40 minutes.34
The drug is eliminated mainly via feces and to a lesser 
extent in the urine. A preclinical study illustrated that approx-
imately 90% of administered bendamustine was recovered 
in feces.30 Bendamustine is highly bound to serum protein 
(95%), primarily to albumin.
The experience with bendamustine has demonstrated 
insignificant variation in its pharmacokinetics based on age, 
gender, and existence of mild to moderate renal dysfunction 
or mild hepatic dysfunction.34 Nevertheless, bendamustine 
should be used with caution in patients with mild hepatic 
dysfunction and mild to moderate renal impairment, 
bendamustine should be avoided with more profound fail-
ure (CrCL  40 mL/min, AST or ALT  2.5 upper limit 
of normal (ULN), or total bilirubin 1.3 ULN) as limited 
studies have been executed in these sittings.30
Drug-drug interactions with bendamustine have not been 
well-studied, but due to the role hepatic cytochrome P450 
1A2 enzyme plays in bendamustine biotransformation,33 CYP 
P450 1A2 inhibitors as well as inducers may lead to altered 
serum levels, and dosage adjustment of bendamustine may 
be needed in these situations.
Bendamustine administration  
and recommended dosage
Bendamustine is a water soluble white powder. It is 
infused intravenously over 30 to 60 minutes once daily. 
Prior to bendamustine administration, the powder must be 
reconstituted with sterile water and diluted in normal saline. 
The product is available in single-use 100 mg vials.30
Several doses of bendamustine have been investigated in 
phase I, II and III trials. Significant toxicity was encountered 
in a phase I study in patients with solid tumors when benda-
mustine doses were escalated up to 280 mg/m2.28 Therefore, a 
dose of 260 mg/m2 every 21 days was recommended for further 
studies. When bendamustine was delivered on days 1 and 
2 every 21 days, the maximum tolerated dose (MTD) was 
180 mg/m2.29 In a phase I/II study conducted to evaluate 
bendamustine dosage in 15 pre-treated patients with chronic 
lymphocytic lymphoma (CLL), a dose of 110 mg/m2 was identi-
fied as MTD, and 100 mg/m² on days 1 and 2 of 21-day cycles 
was recommended for future studies.35 In a phase I/II study 
conducted to evaluate the toxicity and efficacy of bendamustine 
combined with mitoxantrone in 22 patients with CLL, the benda-
mustine dose was escalated from 80 mg/m2 to a maximum of 
240 mg/m² and divided into 2 or 3 doses with mitoxantrone 
(8–10 mg/m2).36 Four of 6 patients who received 240 mg/m2 
dose developed grade III infections and myelosuppression. 
A dose of 150 mg/m2 in combination with 10 mg/m2 mito-
xantrone was recommended for further investigations.
The recommended dosage for bendamustine in patients 
with CLL is 100 mg/m2 on days 1 and 2 of a 28-day cycle 
for up to 6 cycles. For NHLs, bendamustine is administered 
at 120 mg/m2 on days 1 and 2 of a 21-day cycle for up to 
8 cycles.30
It is recommended that subsequent cycles of benda-
mustine be delayed if grade IV hematological toxicity is 
experienced, and therapy should be held until recovery of 
blood counts. The recommendations should also be applied 
if significant grade II or higher nonhematological toxicity is 
faced. Subsequent cycles can be reinitiated at reduced doses 
(50 mg/m2 for CLL, and 90 mg/m2 for NHL on days 1 and 2) 
when toxicity is resolved. If recurrent toxicity is seen subse-
quently, further dosage reduction can be applied (25 mg/m2 
for CLL, 60 mg/m2 for NHL on days 1 and 2) for the next 
cycles. Doses can be re-escalated as tolerated in subsequent 
cycles if toxicity subsides.30
Efficacy studies for bendamustine
Although bendamustine is not a new antineoplastic agent, it 
has been recently attained considerable attention in the US 
and is now FDA approved for use in the treatment of CLL 
and indolent NHL. In addition, studies have shown encour-
aging activity in various other malignancies including mul-
tiple myeloma (MM),37 mantle cell lymphoma (MCL), and 
breast cancer.38 The use of bendamustine is currently being Cancer Management and Research 2009:1 158
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investigated in solid malignancies such as nonsmall cell lung 
cancer and breast cancer. In a recent report, bendamustine has 
been acknowledged as one of the major advances that have 
been made in cancer treatment in 2008.39 On October 31, 
2008, bendamustine was approved for the treatment of 
patients with relapsed/refractory indolent B-cell NHL that 
has progressed during or within six months of treatment with 
rituximab or a rituximab-containing regimen, in addition to 
the earlier approval of bendamustine for treating patients 
with CLL on March 20, 2008.40
Bendamustine in preclinical studies
Preclinical studies demonstrated a distinct apoptotic effect 
of bendamustine on cell lines of B-CLL, MM, and NHL.19–22 
Moreover, bendamustine demonstrated exceptional activity 
toward cancer cells resistant to conventional alkylating 
agents.26,41 Animal and in vitro studies, in NHL and CLL 
models, showed synergistic effect of bendamustine in 
combination with rituximab on tumor inhibition.42,43
Bendamustine as a single agent
Bendamustine was investigated in two studies as a single 
agent in chemotherapy-refractory NHL/CLL patients with 
or without prior exposure to purine-analogs. An overall 
response rate (ORR) of 73% and 77% in various histologic 
subtypes was reported.44,45 Bendamustine toxicity was toler-
able, and no alopecia was observed in either study. The major 
reported adverse effect was myelosuppression.
The first study enrolled 58 patients with relapsed indolent 
NHL and CLL (CLL 27, centroblastic/-cytic 22, centrocytic 6, 
immunocytic 3).44 The majorities of patients had advanced 
disease and were heavily pretreated with prior cytotoxic 
regimens, except for purine-analogs or high dose chemo-
therapy. Bendamustine was administered as a single agent 
at 120 mg/m² on days 1 and 2 every 21 days, and a median 
of 6 cycles were given. The study demonstrated an objective 
ORR of 73% (complete response [CR] 11%, partial response 
[PR] 62%) and stable disease (SD) in 10% of 52 patients 
assessable for response and toxicity. The median duration of 
remission and survival time was 16 and 36 months, respec-
tively. Toxicity was acceptable and no treatment-related 
mortality was observed. Reported adverse effects included 
reversible grade I/II hematological and gastrointestinal 
toxicities. Three patients with grade III leukopenia, and 
3 patients with grade II allergic reactions required treatment 
interruption. No alopecia or grade IV toxicity was seen in 
the study. Bendamustine was reported as a safe and active 
therapy in treating relapsed indolent NHL.
In the second phase II study, 5-day cycles of daily 
bendamustine 60 mg/m2 every 4–6 weeks, for a median of 
4 cycles, were administered to 102 pretreated patients with 
indolent NHL (CLL 15, immunocytic 46, MM 25, MCL 5, 
others 11).45 Patients had received a median of 2 prior cytotoxic 
regimens. Bendamustine achieved a 76.5% ORR (CR 10.8%, 
PR 65.7%). Furthermore, histological sub-analysis yielded 
an ORR of 93% in CLL, 82% in NHL, and 52% in MM. 
The median duration of response and median survival for 
all patients was 39 and 29 months, respectively. The median 
duration of response was significantly longer in patients 
with CLL and NHL (39 months for NHL, and not reached 
with CLL), compared to MM (17 months). Treatment was 
associated with grade III/IV hematological toxicity (anemia 
6.9%, thrombocytopenia 11.8% and leukopenia 24.5%) 
and moderate nonhematological toxicities. Less than 5% of 
patients experienced grade III/IV toxicities including revers-
ible impairment of performance status and gastrointestinal 
toxicities. No alopecia was seen. The study demonstrated a 
high response rate for bendamustine in pre-treated indolent 
NHL and absence of cross-resistance with other alkylating 
agents.
The promising results bendamustine achieved in 
chemotherapy-refractory NHL has led to evaluation of its 
efficacy as a single agent in rituximab-refractory NHL and CLL 
in phase II trials.46,47 Inclusion criteria in these studies were 
absence of response or disease progression within 6 months 
of completing treatment with rituximab alone, rituximab and 
chemotherapy, or radioimmunotherapy. Studies reported an 
ORR of 77% and 84% with acceptable adverse effects.
In a multicenter phase II trial, the efficacy of bendamus-
tine was evaluated in 100 patients with rituximab-refractory 
NHL. Preliminary results in 38 patients (FL 53%, CLL/small 
lymphocyte lymphoma (SLL) 26%, extranodal marginal zone 
21%) was presented at the American Society of Hematology 
(ASH) meeting in 2007.46 The majority of the patients had 
advanced disease, and had received a median of 2 prior 
rituximab-containing regimens in addition to a median of 
3 other treatments including chemotherapy and radioimmu-
notherapy. Bendamustine was given at a dose of 120 mg/m2 
on days 1 and 2 every 21 days for 6 to 8 cycles. ORR was 
84% (CR 29%, unconfirmed complete response (CRu) 3%, 
PR 53%), with a median response duration (RD) and PFS of 
9.3 and 9.7 months, respectively. Toxicity was predominantly 
hematological, including grade III/IV leukopenia, thrombo-
cytopenia and anemia in 60%, 24% and 5%, respectively. 
Other observed toxicities included moderate gastrointestinal 
toxicity and fatigue.Cancer Management and Research 2009:1 159
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In a similar multicenter phase II study, 76 patients with 
rituximab-refractory indolent and transformed NHL (FL 46, 
SLL 12, transformed 15, others 3) were treated with single-
agent bendamustine at 120 mg/m² on days 1 and 2 every 
21 days.47 The majority of enrolled patients had advanced 
disease. Of 74 patients evaluable for response, ORR was 77% 
(CR 15%, CRu 19%, PR 43%), and the median duration of 
response was 6.7 months (9 months for patients with indolent 
disease and 2.3 months for patients with transformed disease). 
The median PFS was 7.1 months in all patients (8.3 months 
in patients with indolent disease and 4.2 months for patients 
with transformed disease), and 36% of responses exceeded 
one year. Toxicity included cytopenias (grade III/IV neutro-
penia, thrombocytopenia and anemia in 54%, 25% and 12%, 
respectively), gastrointestinal complaints and fatigue.
Single-agent bendamustine was compared to other thera-
pies for CLL in 2 randomized trials as first- and second-line 
treatment.48,49 Both studies demonstrated superior outcomes 
with bendamustine as compared with standard therapies.
In a phase III study, 319 chemotherapy-naive patients 
with advanced B-cell CLL were randomized to receive 
bendamustine 100 mg/m² on days 1 and 2 or chlorambucil 
0.8 mg/kg on days 1 and 15 every 4 weeks.48 The primary 
end-points of the study were ORR and PFS. Both values 
showed superiority in the bendamustine arm compared 
to chlorambucil (68% vs 31%) and (21.6 vs 8.3 months), 
respectively. OS was a secondary end-point and no significant 
difference was identified between the two arms of the study. 
Of 312 patients assessable for safety, bendamustine was 
associated with a higher incidence of grade III/IV neutropenia 
(40% vs 19%) as well as infectious complications (8% vs 3%) 
compared to chlorambucil.
In the second study, 96 pre-treated patients with relapsed 
or refractory CLL were randomized to receive bendamustine 
100 mg/m² on days 1 and 2 in a 28-day cycle, or fludarabine 
25 mg/m² on days 1 to 5 every 28 days.49 Both regimens 
were administered until best response was reached or to a 
maximum of 8 cycles. The primary end-point of the study 
was PFS. Ninety-five percent of the patients had been pre-
viously treated with chlorambucil-based regimens. Patients 
who received fludarabine or bendamustine therapy had been 
excluded from the study. The bendamustine arm yielded a 
favorable ORR compared to the fludarabine arm (78% vs 
65%) with CR of 29% vs 10%, and a superior PFS (83 vs 
64 weeks) after 2 years median follow up. Although a higher 
incidence of hematologic toxicity occurred in the bendamus-
tine arm, grade III/IV infectious complications were similar 
in both groups (15%).
These studies have demonstrated significant activity 
with single agent bendamustine in patients with indolent 
NHL and CLL. Bendamustine has shown significant activ-
ity in previously treated patients with relapsed or refractory 
NHL/CLL.44,45 Notably, it yielded a response rate approach-
ing 80% in rituximab-refractory disease.46,47 Furthermore, 
bendamustine has demonstrated efficacy in chemotherapy-
naïve CLL patients and demonstrated superior outcomes 
in comparison to standard therapy such as chlorambucil.48 
Finally, bendamustine exhibited a favorable ORR and PFS 
when compared with fludarabine when it was administered 
as a second-line therapy in patients with advanced CLL.49 
These results have led to additional studies exploring the 
merit of using bendamustine in combination with other anti-
neoplastic agents and monoclonal antibodies.
Bendamustine in combination  
with chemotherapy
Bendamustine has been investigated in combination with 
other antineoplastic agents in treating NHL and CLL. A regi-
men consisting of bendamustine, vincristine and prednisone 
(BOP) was associated with overall response rates of 66% to 
90% in patients with indolent NHL.50 Bendamustine has also 
been tested in combination with other agents such as such as 
mitoxantrone, mitoxantrone/methotrexate/prednisone, and 
idarubicin/dexamethasone, with overall response rates of 
48 to 79%.51–53 A phase II study of oral etoposide and benda-
mustine was conducted in thirty-eight pretreated (n = 12) and 
previously untreated patients with indolent NHL and CLL.54 
Bendamustine was given at 100 mg/m2 on day 1 and etopo-
side was given at a dose of 50 mg on days 1 to 5. Treatment 
was administered in 21-day cycles. The study reported an 
ORR of 97% (CR 67%, PR 30%). The regimen was tolerable 
and only minor hematological and gastrointestinal toxicity 
was observed.
In advanced CLL, bendamustine combined with mito-
xantrone achieved an ORR of 86% (CR 27%, PR 59%) in 
22 previously treated patients.36 The majority of the patients 
(20/22) experienced a median time to progression and median 
survival of 10 and 39 months, respectively. Bendamustine 
was administered in escalating doses from 80 mg/m2 to 
240 mg/m² (divided on days 1–3) every 29 days. Significant 
toxicities occurred at the 240 mg/m² dose level and predomi-
nantly consisted of infections and hematologic toxicities, 
and therefore, a dose of 150 mg/m2 was recommended for 
further studies.
The encouraging results achieved with the BOP regimen 
for indolent NHL led to a phase III trial designed to compare Cancer Management and Research 2009:1 160
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its efficacy to standard combination therapy as first-line 
treatment.55 The study recruited 164 untreated patients with 
advanced NHL (FL, MCL and lymphoplasmacytic lymphoma) 
and randomized them to either BOP (bendamustine 60 mg/m² 
days 1–5, vincristine 2 mg on day 1, and prednisone 100 mg/m² 
on days 1–5) or COP (cyclophosphamide 400 mg/m² on 
days 1–5 instead of bendamustine). Treatment was given in 
21-day cycles up to a maximum of 8 cycles. The ORR was 
66% (CR 22%, PR 44%) in the BOP arm and 76% (CR 20%, 
PR 56%) in the COP arm. There was no significant statistical 
difference between these values. However, in responding 
patients, BOP treatment resulted in a longer median time to 
progression, as compared to COP (84+ months vs 28 months, 
P = 0.037). Furthermore, the 5-year projected survival rate was 
significantly longer for those who had responded to BOP, as 
compared to COP (74% vs 56%; P = 0.05). The study exhibited 
variation in survival based on histological subtypes in the BOP 
group. The 5-year OS was 66%, 74%, and 43% (P = 0.03) in 
FL, lymphoplasmacytic, and MCL, respectively. Treatment 
with the COP regimen was associated with a higher incidence 
of grade III/IV leukopenia (34% vs 19%) and anemia (13% vs 
10%) as compared to BOP, although, thrombocytopenia was 
slightly more common in the BOP arm. Grade III/IV alopecia 
occurred more frequently in the COP arm, as compared to the 
BOP group (48% vs 4%). The study concluded that BOP is 
an appealing alternative to COP in managing patients with 
advanced indolent NHL, and the regimen has an acceptable 
toxicity profile.55
In vitro studies using mononuclear cells obtained from 
patients with a leukemic phase of indolent NHL have 
demonstrated a synergistic effect of bendamustine and 
purine-analog combinations on leukemic cells,44 and this 
justified investigating bendamustine in combination with 
fludarabine in a phase I/II study.56 Bendamustine was 
administered in 2 dose levels (level I was 30 mg/m2, and 
level II was 40 mg/m2), with fludarabine 30 mg/m2 on days 
1 to 3 every 28 days. Twenty-nine patients with relapsed or 
refractory NHL (FL 14, MCL 11, lymphoplasmacytic 2, and 
marginal zone 2), with advanced disease were included. One 
death from febrile neutropenia was reported in the level II 
dose group. Of 19 patients treated at the level I dose and 
assessable for response, an ORR of 77% (CR 45%, PR 32%) 
was observed. However, 53% of the responders relapsed after 
a median of 14 months. Hematologic toxicity was the most 
prominent adverse effect of the combination regimen with 
grade III/IV toxicity seen in 73% of cases.56
Despite the high response rate associated with combinations 
of bendamustine with other agents, toxicities were prominent 
and intractable. Therefore, the search for safer combinations 
has been initiated. Rituximab is a chimeric monoclonal 
antibody against CD20. The combination of rituximab with 
bendamustine is discussed in the next section.
Bendamustine in combination  
with rituximab
The experience of the bendamustine, rituximab, and mito-
xantrone (BMR) combination has yielded a response rate 
approaching 90%.57–59 This outpatient regimen was tested 
initially in a phase I/II prospective study in 20 pre-treated 
patients with advanced NHL/CLL (FL 9, CLL 4, lympho-
plasmacytic 3, secondary high grade 4).57 Patients were given 
bendamustine 90 mg/m2 (80 mg/m² for CLL) on days 1 to 3, 
mitoxantrone 10 mg/m2 on day 1, and rituximab 375 mg/m² 
weekly in weeks 2 to 5. Cycles were administered every 
36 days or sooner after blood counts recovered, for a maxi-
mum of 5 cycles. The regimen achieved an ORR of 95% 
(CR 35%, PR 60%), and only one patient with secondary 
high grade lymphoma had progressive disease. At seven 
months follow-up, 75% of patients continued to respond to 
treatment.
An updated analysis including 54 patients with symp-
tomatic relapsed or refractory NHL/CLL (B-CLL 21, B-cell 
prolymphocytic leukemia 1, FL 14, lymphoplasmacytic 8, 
MCL 2, marginal 2, secondary high grade 6) treated with the 
BMR regimen has been published.58 The ORR in the study 
was 96% (CR 41%, PR 55%). The ORR varied with histo-
logical types and was reported as 100%, 95%, and 83% in 
indolent NHL, CLL, and secondary high grade lymphomas, 
respectively. The median time to progression was 17 months 
for CLL and had not been reached for indolent NHL after 
27 months median follow-up. No treatment associated 
deaths or hospitalizations were observed. Myelosuppres-
sion was the main toxicity, with grade III/IV symptomatic 
and asymptomatic hematologic toxicity in 19% and 43% of 
patients, respectively. No grade III/IV nonhematological 
toxicity was reported.
The promising outcomes BMR obtained from the single 
center reports has led to a phase II multicenter study which 
enrolled 57 patients with advanced relapsed or refractory 
indolent lymphomas or MCL (FL 29, MCL 18, other indo-
lent lymphomas 10).59 Thirty-nine percent of patients had 
received prior treatment with rituximab-containing regimens. 
The ORR was 89% (CR 35%, PR 54%) in all patients, and 
76% in patients who had received a rituximab-containing 
regimen. The estimated PFS during 27 months follow-up 
was 19 months. Sub-group analysis revealed an ORR of 92% Cancer Management and Research 2009:1 161
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for FL versus 78% for MCL. The 2-year OS was similar in 
both groups. Grade III/IV toxicities were predominantly 
myelosuppression (leukopenia 78%, anemia 10%, and throm-
bocytopenia 16%). Other observed grade III/IV toxicities 
include gastrointestinal toxicity, alopecia (5%), and cardiac 
toxicity (7%). Unexpected hospitalization occurred in 4% 
of patients.
The combination of bendamustine and rituximab (BR) 
has also been associated with durable responses and a favor-
able toxicity profile. In a phase II multicenter trial in patients 
with relapsed or refractory NHL or MCL (FL 24, MCL 16, 
lymphoplasmacytoid, marginal zone 6), the BR combination 
was administered for a maximum of 4 cycles every 28 days.60 
Bendamustine 90 mg/m² was administered on days 1 and 2 
of each cycle. The combination was associated with a 90% 
ORR (CR 60%, PR 30%). The median PFS was 24 months. 
Sub-group analysis revealed an ORR of 75% in MCL and 
96% in FL. The treatment was well tolerated, and toxicity 
was mainly myelosuppression. Grade III/IV leukopenia, 
thrombocytopenia and anemia was seen in 19%, 4% and 1% 
of patients, respectively.
In a similar phase II trial the BR regimen was used in 
67 patients with relapsed indolent NHL or MCL, in the 
absence of prior documented rituximab resistance.61 The 
regimen consisted of bendamustine (90 mg/m² on days 2 and 
3 every 28 days) in combination with rituximab on day 1. 
Sixty-six patients (FL 40, small lymphocytic 10, MCL 12, 
other indolent 4) received at least one treatment. The ORR 
was 92% (CR 41%, CRu 14%, PR 38%). Sub-group analysis 
revealed an ORR of 86% in patients with prior rituximab 
exposure (37 patients) versus 100% in patients without 
prior rituximab exposure (29 patients). The median duration 
of response and PFS was 21 and 23 months, respectively. 
No significant difference in response rate was observed 
between patients with indolent NHL or MCL. Myelosuppres-
sion was the major toxicity. Grade III/IV neutropenia and 
thrombocytopenia occurred in 36% and 95%, respectively.
The most interesting data was derived from a phase III 
multicenter trial including 546 patients randomized to BR 
(bendamustine at 90 mg/m2 on days 1 and 2 every 28 days) 
or CHOP-R (up to 6 cycles) as first-line therapy for indolent 
NHL or MCL.62 The histologic subtypes were equally 
distributed in both arms of the study (FL 52%, MCL 20%, 
other indolent lymphomas 28%). The ORR was 94% 
(CR 41%) in patients who received BR as compared to 
93% (CR 33%) in patients who received CHOP-R. The 
primary end-point of the study (event-free survival [EFS]) 
was not reached in the BR group, compared to 39 months in 
CHOP-R group. Relapse or progression was noted in 58 and 
75 patients treated with BR and CHOP-R, respectively. 
The mortality rate was similar in each group, although less 
toxicity was seen in the bendamustine arm (alopecia 0% vs 
89%, infectious complications 25% vs 37%, and grade III/IV 
leukopenia 19% vs 36%).
Since elderly patients are less able to tolerate aggressive 
therapy, a phase II trial targeting patients older than 75 years 
was conducted to assess the efficacy and safety of the BR 
combination (bendamustine at dose of 90 mg/m² on days 1 
and 2 every 28 days) in patients with indolent NHL and 
MCL.63 The median age of patients was 79 years. The ORR 
was 88% (CR 35%) in 26 patients assessable for response. 
Major toxicities of the regimen were due to myelosup-
pression.
Preclinical studies have documented that the addition of 
rituximab can reduce the bendamustine dose that is required 
to induce apoptosis in ex vivo B-CLL cells.42,43 Therefore, 
a phase II trial was conducted in 81 pre-treated patients 
with refractory or relapsed CLL using the BR regimen.64 
Bendamustine (70 mg/m² on days 1 and 2 every 28 days) 
was administered in combination with rituximab (375 mg/m² 
on the first cycle, then 500 mg/m² for subsequent cycles) for 
up to 6 cycles. The ORR was 77.4% (CR 14.5, PR 62.9) in 
62 patients assessable for response. Disease progressed in 
4.8% of cases. Sub-groups analysis revealed variable outcomes 
based on molecular cytogenetic profile of the tumor. Three 
treatment-related deaths occurred secondary to infectious 
complications. Other adverse effects were grade III/IV 
leukopenia, thrombocytopenia, and anemia occurring in 
11.9%, 9.1%, and 6.1% of patients, respectively.
These studies demonstrate the activity of the BR regimen 
in treating relapsed or refractory indolent NHL and CLL. This 
combination has shown high response rates with efficacy 
equivalent to standard therapies in addition to a favorable 
toxicity profile in groups such as the elderly (Table 1).
Safety and tolerability 
of bendamustine
The most common toxicity of bendamustine is hematological 
secondary to bone marrow suppression. However, an 
in vitro study showed less stem cell toxicity associated with 
bendamustine as compared to fludarabine.65 Blood counts 
should be monitored closely during the course of therapy, 
and schedule delays have been advocated for patients who 
experience significant myelosuppression. Treatment can be 
reinitiated at reduced doses after hematopoietic recovery 
(ANC  1 × 109/L and platelet count 75 × 109/L).30Cancer Management and Research 2009:1 162
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Infectious complications including pneumonia and sepsis 
have been reported during bendamustine use, and certain 
cases have been complicated by septic shock and even death. 
Therefore, patients on bendamustine therapy should report 
early signs of infection to prevent advanced complications.
Aside from hematological toxicities, bendamustine is 
associated gastrointestinal toxicities (including nausea, vom-
iting, constipation, and diarrhea), fatigue, pyrexia, asthenia, 
weight and appetite loss, dehydration, and cardiac compli-
cations. Most nonhematological toxicities occur in mild to 
moderate severity. Skin reactions have been reported during 
bendamustine therapy.
Infusion reaction and anaphylaxis is a potential risk after 
the initial cycle bendamustine therapy.30,47 Bendamustine 
should be discontinued if severe reaction occurs. For mild 
reactions, patients need to be pretreated with antihistamines, 
antipyretics and corticosteroids. Tumor lysis syndrome is a 
serious risk when bendamustine therapy is initiated and pro-
phylactic measures should be taken in high risk patients.
In comparison to other alkylating agents, bendamustine 
use has been associated with substantially less alopecia when 
compared with other alkylating agents.
Bendamustine is classified as a Pregnancy Category D 
medication. Bendamustine injection during organogenesis 
in rodents resulted in decreased body weights and increased 
fetal malformations. Therefore, women of childbearing 
age should avoid pregnancy with adequate birth control 
methods.30
Conclusion
Bendamustine has emerged as a unique alkylating agent for 
the treatment of indolent lymphomas, with only partial cross-
resistance to other alkylating agents. Use of bendamustine 
either as a single agent or in combination with other cytotoxic 
agents or rituximab has yielded promising outcomes, espe-
cially when it has been applied in the context of rituximab-
refractory indolent lymphomas. Single agent bendamustine 
has shown superiority as a first- and second-line therapy for 
indolent NHL over standard therapies such as chlorambucil 
and fludarabine. Furthermore, in combination with rituximab, 
bendamustine achieved equivalent efficacy to the CHOP-R 
regimen in treating indolent NHL, and the combination had 
been employed safely and effectively in managing elderly 
patients. Studies have shown a favorable toxicity profile for 
bendamustine limited primarily to myelosuppression.
Although bendamustine has exhibited significant 
activity toward lymphoid malignancies, additional studies 
are warranted to define the optimal doses and schedules, 
subgroups that benefit the most from the agent, and novel 
combinations.
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